Anemia in Cancer: Some Pathophysiological Aspects
Tóm tắt
After completing this course, the reader will be able to:
Recognize the causes of anemia in cancer patients. Describe ways in which the action of erythropoietin is regulated. Explain the methods for treating anemia and indications for treatment.
Access and take the CME test online and receive one hour of AMA PRA category 1 credit at CME.TheOncologist.com
More than 30% of cancer patients experience anemia and its side effect, fatigue. Its causes can be numerous, but anemia is usually secondary to an imbalance of cytokines. Among these, tumor necrosis factor-alpha seems to be the major culprit, creating anemia by blunting the physiological effect of erythropoietin. Pharmacologically increasing the erythropoietin level corrects the anemia in about half the treated patients. Several studies have shown that quality of life is substantially improved through such therapy.
Từ khóa
Tài liệu tham khảo
Mercadante, 2000, Anemia in cancer: pathophysiology and treatment, Cancer Treat Rev, 26, 303, 10.1053/ctrv.2000.0181
Digicaylioglu, 2001, Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades, Nature, 412, 641, 10.1038/35088074
Yu, 2001, The human erythropoietin receptor gene rescues erythropoiesis and developmental defects in the erythropoietin receptor null mouse, Blood, 98, 475, 10.1182/blood.V98.2.475
Papadaki, 2002, Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti-tumor necrosis factor-alpha antibody therapy, Blood, 100, 474, 10.1182/blood-2002-01-0136
Curt, 2000, Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition, The Oncologist, 5, 353, 10.1634/theoncologist.5-5-353
Littlewood, 2001, Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial, J Clin Oncol, 19, 2865, 10.1200/JCO.2001.19.11.2865
Glaspy, 2002, Comparable efficacy of epoetin alfa for anemic cancer patients receiving platinum- and nonplatinum-based chemotherapy: a retrospective subanalysis of two large, community-based trials, The Oncologist, 7, 126, 10.1634/theoncologist.7-2-126
Adamson, 1999, Predicting the hematopoietic response to recombinant human erythropoietin (Epoietin alfa) in the treatment of the anemia of cancer, Oncology, 56, 46, 10.1159/000011929
Wu, 2001, Blood transfusion in elderly patients with acute myocardial infarction, N Engl J Med, 345, 1230, 10.1056/NEJMoa010615
Lavey, 1999, Tumor Hypoxia, 99